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A 67-year old man was diagnosed with advanced prostate cancer with multiple pelvic lymph nodes and
multiple bone metastases (cT2N1M1b), with an initial prostate speciﬁc antigen of 1,300 ng/ml. Prostate
biopsy specimens revealed poorly differentiated adenocarcinoma, Gleason’s score 5＋3. He was treated
with maximal androgen blockade (MAB) from 2001, but showed resistance to hormone therapy and
docetaxel in 2007. External radiation therapy for bone pain was difﬁcult due to multiple lesions. 89Sr
therapy was started in 2009. The therapy could be performed 5 times without any side effects. Good pain
control and decreasing PSA was obtained at each dose.
(Hinyokika Kiyo 58 : 515-518, 2012)














現病歴 : 2001年 3月排尿痛にて近医を受診．直腸診
にて前立腺両葉とも石様硬，PSA 330 ng/ml と高値の
ため 4月当院紹介となった．
初診時の血液検査で PSA 1,300 ng/ml まで上昇して
おり，ALP 737 ng/ml と高値を認めた以外は正常範囲
であった．前立腺針生検で 4本すべて Gleason’s score
5＋3 の前立腺癌を検出．CT で両側内外腸骨リンパ
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Fig. 1. Bone scintigraphy (99 mTc-HMDP) at the
ﬁrst visit.
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Fig. 2. 8-year clinical course from the ﬁrst visit.
節腫大，骨シンチで多発骨転移 (EOD3) (Fig. 1) を認
め，cT2cN1M1b stage IV の前立腺癌と診断した．

















に高い鎮痛効果と PSA の低下を認めた (Fig. 4）．骨代












ムの放射性同位元素の 1つである 89Sr は半減期50.5
日，β 線を平均 2.4 mm 放出することで有痛性骨転移
の疼痛緩和に対して効果を発揮する．1942年に











泌尿紀要 58巻 9号 2012年516
泌58,09,12-4




















Fig. 5. Suggested treatment strategy for CRPC with
multiple bone metastasis.
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